Feature|Videos|April 10, 2025
Navigating the Biopharma Landscape: Rentschler's Strategic Shift to Biologics
Author(s)Rentschler Biopharma
Benedikt von Braunmühl, CEO of Rentschler Biopharma, discusses the company's strategic shift toward biologics CDMO services.
Rentschler Biopharma is pivoting to biologics CDMO services to better align with evolving market demand. Watch this video to learn more about:
- Why the company is undergoing this strategic shift.
- Where the biopharma market is heading, especially in the US and Europe.
- How the company's new strategic orientation supports clients globally to navigate the current (geopolitical) market situation.
Related Content
Choosing the Right CDMO for Long-Term Stability
Published: | Updated:
Sponsored
Reducing Timelines and Eliminating the White Space in Complex Biologic & Bioconjugate Development
Published: | Updated:
Sponsored
